A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

2025-523847-36-00 Protocol J3R-MC-YDAH Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 19 May 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol J3R-MC-YDAH

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 32
Countries 1
Sites 1

Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function

Key facts

Sponsor
Eli Lilly & Co.
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06], Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
19 May 2026 → ongoing
Decision date (initial)
2026-04-14
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-523847-36-00
WHO UTN
U1111-1332-1074

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Eli Lilly & Co.

Sponsor organisation
Eli Lilly & Co.
Address
1 Lilly Corporate Center
City
Indianapolis
Postcode
46285-0001
Country
United States

Scientific contact point

Organisation
Eli Lilly & Co.
Contact name
Lilly Clinical Trials information desk

Public contact point

Organisation
Eli Lilly & Co.
Contact name
Lilly Clinical Trials information desk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ongoing, recruiting 12 1
Rest of world
United States
20

Investigational sites

Hungary

1 site · Ongoing, recruiting
CRU Hungary Kft.
NA, Semmelweis Ter 1, 2143, Kistarcsa

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2026-05-19 2026-05-20

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-15 Hungary Acceptable
2026-04-13
2026-04-14